1. Striational antibodies in a paraneoplastic context.
- Author
-
McKeon A, Lennon VA, LaChance DH, Klein CJ, and Pittock SJ
- Subjects
- Adenocarcinoma complications, Adenocarcinoma immunology, Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Humans, Male, Middle Aged, Myasthenia Gravis etiology, Myasthenia Gravis immunology, Neoplasms complications, Paraneoplastic Syndromes etiology, Retrospective Studies, Sarcoma complications, Sarcoma immunology, Thymoma complications, Thymoma immunology, Thymus Neoplasms complications, Thymus Neoplasms immunology, Autoantibodies immunology, Muscle Proteins immunology, Neoplasms immunology, Paraneoplastic Syndromes immunology
- Abstract
Introduction: The clinical significance of striational antibodies (StrAbs) detected in the course of paraneoplastic antibody testing is unknown., Methods: We compared all 203 striational antibody (StrAb)-seropositive patients identified (2004-2005) during evaluation for paraneoplastic antibodies with age- and sex-matched seronegative controls., Results: Thymoma and myasthenia gravis (MG) were significantly more common among cases (P<0.0001). Cancers more rarely detected after StrAb detection were adenocarcinoma in 5 patients and sarcoma in 3 patients. All patients who had a cancer identified after StrAb testing had a titer of ≥ 1:7680 or a coexisting muscle AChR-binding antibody. Autoimmune disorders more commonly observed among cases (with any StrAb value) included: hypothyroidism; rheumatoid arthritis; and pernicious anemia (all P<0.05)., Conclusions: StrAbs may serve as a diagnostic clue for an autoimmune diagnosis. There is a low likelihood of oncological significance in patients with StrAb titers <1:7680 without coexisting paraneoplastic Abs., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF